Publicaciones (41) Publicaciones en las que ha participado algún/a investigador/a

2021

  1. Association between coffee consumption and total dietary caffeine intake with cognitive functioning: cross-sectional assessment in an elderly Mediterranean population

    European Journal of Nutrition, Vol. 60, Núm. 5, pp. 2381-2396

  2. Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies

    Annals of Medicine, Vol. 53, Núm. 1, pp. 762-769

  3. Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors

    Frontiers in Endocrinology, Vol. 12

  4. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

    The Lancet Oncology, Vol. 22, Núm. 4, pp. 463-475

  5. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 8

  6. Consensus of the Spanish society of laboratory medicine and the Spanish society of medical oncology on the methodology and criteria for evaluation of circulating tumour markers in breast cancer

    Clinical and Translational Oncology, Vol. 23, Núm. 7, pp. 1272-1280

  7. Development and validation of an early mortality risk score for older patients treated with chemotherapy for cancer

    Journal of Clinical Medicine, Vol. 10, Núm. 8

  8. Discovery and proof-of-concept study of nuclease activity as a novel biomarker for breast cancer tumors

    Cancers, Vol. 13, Núm. 2, pp. 1-16

  9. Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice

    OncoTargets and Therapy, Vol. 14, pp. 5345-5352

  10. Early imaging and molecular changes with neoadjuvant bevacizumab in stage ii/iii breast cancer

    Cancers, Vol. 13, Núm. 14

  11. Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: A 3-month follow-up analysis

    BMJ Supportive and Palliative Care, Vol. 11, Núm. 1, pp. 25-31

  12. Electronic health records and patient registries in medical oncology departments in Spain

    Clinical and Translational Oncology, Vol. 23, Núm. 10, pp. 2099-2108

  13. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?

    Gastric Cancer, Vol. 24, Núm. 2, pp. 445-456

  14. Factors that Influence Treatment Delay for Patients with Breast Cancer

    Annals of Surgical Oncology, Vol. 28, Núm. 7, pp. 3714-3721

  15. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

    Annals of Oncology, Vol. 32, Núm. 10, pp. 1245-1255

  16. First-line osimertinib in patients with epidermal growth factor receptor–mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met

    European Journal of Cancer, Vol. 159, pp. 174-181

  17. Identification of a dexamethasone mediated radioprotection mechanism reveals new therapeutic vulnerabilities in glioblastoma

    Cancers, Vol. 13, Núm. 2, pp. 1-23

  18. Incidence and clinical pattern of contralateral synchronous and metachronous germ cell testicular cancer

    Urologic Oncology: Seminars and Original Investigations, Vol. 39, Núm. 2, pp. 135.e17-135.e23

  19. Integrated mrna and mirna transcriptomic analyses reveals divergent mechanisms of sunitinib resistance in clear cell renal cell carcinoma (Ccrcc)

    Cancers, Vol. 13, Núm. 17

  20. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

    Nature Communications, Vol. 12, Núm. 1